Evidence map›Paper›PMID 32875231›Full record

ArticleACS omega2020

Synthesis of a

Mark H Dornan, Daniil Petrenyov, José-Mathieu Simard, Mehdi Boudjemeline, Roxana Mititelu, Jean N DaSilva, Anthony P Belanger

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.2field-weighted citation impact, top 50% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Mark H DornanDepartment of Imaging, Dana-Farber Cancer Institute & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Daniil PetrenyovLaboratoire de Radiochimie et Cyclotron, Centre de Recherche du Centre Hospitalier de l'Université de Montréal & Département de Radiologie, radiooncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.
José-Mathieu SimardLaboratoire de Radiochimie et Cyclotron, Centre de Recherche du Centre Hospitalier de l'Université de Montréal & Département de Radiologie, radiooncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.
Mehdi BoudjemelineLaboratoire de Radiochimie et Cyclotron, Centre de Recherche du Centre Hospitalier de l'Université de Montréal & Département de Radiologie, radiooncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.
Roxana MititeluDivision of Dermatology, Department of Medicine, McGill University, Montreal, Quebec H4A 3J1, Canada.
Jean N DaSilvaLaboratoire de Radiochimie et Cyclotron, Centre de Recherche du Centre Hospitalier de l'Université de Montréal & Département de Radiologie, radiooncologie et médecine nucléaire, Faculté de médecine, Université de Montréal, Montréal, Quebec H3T 1J4, Canada.
Anthony P BelangerDepartment of Imaging, Dana-Farber Cancer Institute & Department of Radiology, Harvard Medical School, Boston, Massachusetts 02115, United States.
Centre Hospitalier de l’Université de Montréal · CAHarvard University · USMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The serine/threonine kinase B-Raf is an essential regulator of cellular growth, differentiation, and survival. B-Raf protein expression is elevated throughout melanoma progression, making it an attractive target for noninvasive imaging using positron-emission tomography. Encorafenib is a potent and highly selective inhibitor of B-Raf used in the clinical management of melanoma. In this study, the radiosynthesis of a

Identifiers

PMID32875231
PMCPMC7450646
OpenAlexW3049717158

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.